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Abstract
Background: 1) To identify socio-demographic factors associated with parental “no-intent” for their 13–17 year old
unvaccinated daughter to receive the human papillomavirus (HPV) vaccine series within the next twelve months, 2)
to describe patterns in “no-intent” by socio-demographic factors, and 3) to identify socio-demographic factors
associated with parental reasons for “no-intent”.
Methods: Data from 2008–2012 National Immunization Survey - Teen (NIS - Teen) were examined in this study.
Parents with “no-intent” to vaccinate their daughters were asked to identify reasons for their decision. All responses
were categorized into five domains identified as barriers to receive the HPV vaccine series: 1) Safety and Effectiveness
Concerns; 2) Systemic Barriers; 3) Vaccine Misinformation; 4) Lack of Knowledge about the Vaccine; and 5) Socio-cultural
Barriers. Multivariable logistic regression models were performed to address the study objectives.
Results: Number of people in the household, household income, mother’s age, education, health insurance,
recommendation of a health care provider, and the survey year were significantly associated with parental
“no-intent”. Race/ethnicity, mother’s education, marital status, recommendation of a health care provider, household
income, age of the unvaccinated daughter, and the survey year, were significantly associated with one or more
domains identified as barriers to receive the HPV vaccine.
Conclusions: This study identified sub-groups of parents across different socio-demographic factors with “no-intent”
for their adolescent daughters to receive the HPV vaccine. Developing strategies that target educational tools towards
the identified sub-groups of parents about the purpose, safety, and efficacy of the HPV vaccine, and HPV infection, may
help increase HPV vaccine acceptance, initiation and completion rates.
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Background
In the United States (U.S.), human papillomavirus
(HPV) is the most prevalent sexually transmitted infec-
tion (STI) with up to 24.5% HPV infection among fe-
males aged 14–19 years [1–3]. HPV types 6 and 11,
cause 90% of genital warts and HPV types 16 and 18,
cause 70% of cervical cancers [4]. Oncogenic HPV also
causes vulvar, vaginal, anal cancers [5, 6]. In 2012, there
were two highly efficacious HPV vaccines on the market
licensed by The Food and Drug Administration (FDA);
the bivalent vaccine (Ceravix) which provides protection
against high-risk oncogenic HPV types 16 and 18 only,
and the quadrivalent vaccine (Gardasil) which provides
protection against types 16 and 18, as well as two low
risk types 6 and 11 [7–9]. In 2014, the 9-valent (Gardasil
9) virus-like particle HPV vaccine was approved which
has the potential to increase cervical cancer prevention
from 70% to 90% [10, 11]. The Healthy People 2020 goal
for HPV vaccine coverage among female adolescents
aged 13–15 years in the U.S. is 80% [12]. Among females
* Correspondence: vcheruvu@kent.edu
Department of Biostatistics, Environmental Health Sciences, and
Epidemiology, College of Public Health, Kent State University, Hilltop Drive,
320 Lowry Hall, Kent 44242, OH, USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cheruvu et al. BMC Pediatrics  (2017) 17:52 
DOI 10.1186/s12887-017-0804-1
aged 14–19 years, Markowtiz and colleagues reported a
decline in the prevalence of vaccine preventable HPV
infections from 11.5% in 2003–2006 (the pre-vaccine
era) to 5.1% in 2007–2010 (the post-vaccine era) [13].
Despite a significant increase in HPV vaccination
coverage during 2007–2011, the increase in the per-
centage of unvaccinated girls with at least one missed
opportunity for HPV vaccination from 20.8% to 84.0%
is a major public health concern [14]. These numbers
highlight the potential of the HPV vaccine, the im-
portance of developing educational strategies for par-
ents about the vaccine, and the need for targeting
vaccination campaigns towards adolescents to reduce
HPV infections and their sequelae, most notably geni-
tal warts and cervical cancer.
A considerable number of studies have focused on
the factors associated with initiation and completion
of the HPV vaccine series [15–30]. For example, two
studies reported older age of adolescent females was
associated with initiation and completion of HPV vac-
cination [22, 23]. Only recently, the research focus
has shifted to understand the population of unvaccin-
ated teens, factors associated with “intent”, and paren-
tal reasons for “no-intent” for their daughters to
receive the HPV vaccine [25–35]. However, such stud-
ies were limited in that they only reported the most
common reasons cited by parents for “no-intent” to
vaccinate their adolescents, while failing to identify
the underlying socio-demographic characteristics of
such parents. Parental attitudes and beliefs regarding
vaccines in general and the HPV vaccine in particular,
affect the likelihood that their children will receive
vaccines [36]. It is particularly important that we
identify these socio-demographic sub-groups and de-
velop targeted strategies to improve acceptance and
uptake of the HPV vaccine.
In a recent study among unvaccinated females aged
15–25 years, Liddon and colleagues described the corre-
lates of the main reasons for foregoing vaccination in fe-
males [33]. However, to our knowledge, factors
associated with various self-disclosed parental reasons
for “no-intent” to vaccinate their daughters have not
been studied in a nationally representative sample of un-
vaccinated female adolescents aged 13–17 years.
In this study, we used a sub-sample of unvaccinated fe-
males aged 13–17 years from the National Immunization
Survey - Teen (NIS - Teen), 2008–2012, to address three
specific objectives: 1) To identify socio-demographic fac-
tors associated with parental “no-intent” for their 13–17
year old unvaccinated daughter to receive the human pap-
illomavirus (HPV) vaccine series in the next twelve
months, 2) to describe patterns in “no-intent” by socio-
demographic factors, and 3) to identify socio-demographic
factors associated with parental reasons for “no-intent”.
Methods
National Immunization Survey-Teen (NIS-Teen)
Data from 2008–2012 NIS-Teen surveys were used for
the analyses [37]. The NIS-Teen survey is implemented
annually by the National Center for Immunization and
Respiratory Diseases and the National Center for Health
Statistics of the Centers for Disease Control and Preven-
tion. It represents a stratified national probability sample
of households in the U.S. that include all 50 states, the
District of Columbia, and the U.S. Virgin Islands. Details
about methodology and weighting procedures, have been
previously published [38]. All estimates were based on ad-
olescents with adequate provider data. The observations
from the U.S. Virgin Islands were excluded from all ana-
lyses. The final sample size was 23,722. This study was ex-
empt from review by Kent State University’s IRB because
NIS - Teen data are publicly available and deidentified.
No-intent to receive the HPV vaccine series
Parent (or guardian) of a female adolescent with no his-
tory of HPV vaccination at the time of the interview was
asked the question “how likely is it the teen will receive
HPV vaccinations in the next 12 months?”. Of the five
possible responses, parents who responded “very likely”
or “somewhat likely” were considered as having “intent”
and those who responded “not too likely”, “not likely at
all”, or “not sure/do not know” were considered as hav-
ing “no-intent” for their daughter to receive the HPV
vaccine series within the next 12 months. The percent-
age of parents who responded “not sure/do not know”
was very small (<3%). Parents with “no-intent” were then
asked the question, “What is the main reason [your teen]
will not receive HPV shots in the next 12 months? “ Par-
ents were allowed to report one or more reasons from a
list which CDC created. For the present analyses, we
created the following five domains for the reasons par-
ents reported: i) Safety and Effectiveness Concerns, ii)
Systemic Barriers, iii) Vaccine Misinformation, iv)
Lack of Knowledge about the Vaccine, and v) Socio-
cultural Barriers. Table 1 shows the questions that
went into each domain created based on qualitative
groupings. Each domain is treated as a binary outcome
in our analyses: “Yes” if a parent reported at least one of
the reasons and “No” if no reason was reported in the
corresponding domains.
Statistical analysis
Of the 23,722 unvaccinated females (2008: n = 5,126;
2009: n = 4,901; 2010: n = 4,614; 2011: n = 5,231; and
2012: n = 3,850), 21,467 had information on all the co-
variates of interest. Of these, parents of 12,716 females
were in the “no-intent” group, of which 12,274 of them
reported at least one reason for their decision.
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The unadjusted weighted prevalence estimates with
95% confidence intervals (CIs) were computed to de-
scribe the socio-demographic characteristics of unvac-
cinated female adolescents. Univariate analyses were
performed to test for associations between socio-
demographic factors and parental “intent” vs. “no-in-
tent” for their daughters to receive the HPV vaccine
series within the next 12 months. Multivariable logis-
tic regression analysis was performed to determine
the factors associated with “no-intent”. To describe
how the socio-demographic factors associated with
parental “no-intent” changed over time, we computed
the unadjusted weighted prevalence estimates with
95% CIs for each survey year. The sample size for
these analyses was 21,467. To determine how the
socio-demographic factors associated with parental
reasons for “no-intent”, we performed multivariable
logistic regression analysis treating the five domains
as binary outcomes (Yes/No) correspondingly. The
sample size for these analyses was 12,274.
Sampling weights provided in the 2008–2012 NIS - Teen
public use data were used to obtain population-based
estimates. All analyses were performed using SAS® version
9.3 (Cary, NC, USA) survey procedures (PROC SURVEY-
FREQ, PROC SURVEYMEANS, PROC SURVEYLOGIS-
TIC) to account for the complex sampling design of the
NIS-Teen data. All analyses were conducted in 2014.
Results
Sample characteristics
Overall, 51.1% (95% CI: 50.3%–52.0%) of the female ado-
lescents were completely unvaccinated for HPV [2008:
61.0% (95% CI: 58.9%–63.0%) ; 2009: 53.9% (95% CI:
52.0%–55.7.0%) ; 2010: 52.0% (95% CI: 50.1%–53.8%) ;
2011: 46.8% (95% CI: 45.1%–48.4%) ; 2012: 42.0% (95%
CI: 40.1%–43.7%)]. The mean age of these adolescents
was 14.3 years. Table 2 presents the socio-demographic
characteristics of the unvaccinated adolescent females in
this study. Sixty percent were White non-Hispanic,
71.6% of mothers of unvaccinated females were married,
33.6% were college graduates, and 46.6% of were be-
tween the ages 35–44. Sixty-three percent reported that
a healthcare provider had not recommended that their
daughter receive the HPV vaccine series.
Socio-demographic factors associated with no-intent to
receive the HPV vaccine series
During 2008–2012, 59.9% (95% CI: 58.7%–61.1%) of par-
ents of unvaccinated adolescent females indicated that
they did not intend to have their daughters vaccinated
against HPV within the next 12 months. Table 3 de-
scribes the socio-demographic characteristics of unvac-
cinated females across “no-intent” vs. “intent” groups
and presents the factors significantly associated with par-
ents’ “no-intent” to vaccinate their daughters: number of
people in the household (Adjusted Odds Ratio: AOR:
1.05 [95% CI: 1.01–1.10]); annual household income of
$35,001–$75,000 (AOR: 1.21 [95% CI: 1.02–1.44]) com-
pared to ≤ $35,000; mothers with some college education
(AOR: 1.44 [95% CI: 1.16–1.79]) or who are college
graduates (AOR: 1.28 [95% CI: 1.03–1.60]) compared to
mothers with less than high school education ; mothers
≥45 years of age (AOR: 1.32 [95% CI: 1.06–1.65]) com-
pared to younger mothers (≤34 years); “Other” insurance
(AOR: 1.36 [95% CI: 1.05–1.75]) compared to private in-
surance; no recommendation from a health care pro-
vider (AOR: 2.02 [95% CI: 1.82–2.53]) compared to
recommendation from a health care provider; and the
survey year, 2009 (AOR: 1.30 [95% CI: 1.10–1.52]), 2010
(AOR: 1.57 [95% CI: 1.33–1.86]), 2011 (AOR: 1.25 [95%
CI: 1.06–1.47]), and 2012 (AOR: 1.26 [95% CI: 1.06–
1.50]) compared to survey year 2008. Parents who iden-
tified as Hispanics were significantly less likely to report
no-intent to vaccinate their daughters (AOR: 0.79 [95%
CI: 0.66–0.95]) compared to White, non-Hispanics.
Patterns in no-intent to receive the HPV vaccine series,
2008–2012
Table 4 presents patterns across survey years in parental
“no-intent” for their daughters to receive the HPV vac-
cine series within the next 12 months, by socio-
demographic characteristics. Among parents who did
Table 1 Reasons for no-intent to receive human papillomavirus
vaccine (HPV) series among unvaccinated female adolescents aged
13–17 years, National Immunization Survey - Teen, 2008-2012
Domain Reason # Main reason teen will not receive




HPVI_REAS_11 Safety Concern/Side Effects
HPVI_REAS_12 Effectiveness Concern
HPVI_REAS_21 More info/New Vaccine
Systemic Barriers HPVI_REAS_1 Not Recommended
HPVI_REAS_10 Costs
HPVI_REAS_23 Not Available
HPVI_REAS_24 Not a School Requirement
HPVI_REAS_26 No OB/GYN




HPVI_REAS_2 Not Needed or Not Necessary
HPVI_REAS_5 Not Sexually Active
HPVI_REAS_6 Not Appropriate Age
HPVI_REAS_25 Increased Sexually Activity Concern
Lack of Knowledge
about the Vaccine
HPVI_REAS_3 Lack of Knowledge
Socio-cultural
reasons
HPVI_REAS_16 Don’t Believe in Immunizations
HPVI_REAS_17 Family/Parental Decision
HPVI_REAS_19 Religion/Orthodox
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not receive a health care provider recommendation for
their daughter to receive the HPV vaccine series, the
proportion of parents who reported “no-intent” was sig-
nificantly lower in survey year 2012 (35.0%, 95% CI:
32.2–37.7%) when compared to survey years 2008
(44.3%, 95% CI: (41.5–47.2%), 2009 (42.0%, 95% CI:
39.2–44.8%), and 2010 (44.9%, 95% CI: 42.2–47.6%).
Additionally, there was a significant increase through
survey years 2009–2012 when compared to survey year
2008 among the following factors: mothers with a col-
lege education, mothers 45 years of age or older, and
higher income were all associated with an increase in
the proportion of parents who reported “no-intent”.
Factors associated with reasons for “no-intent” to receive
the HPV vaccine series
Of the 12,274 parents who reported “no-intent” for their
daughters to receive the HPV vaccine series within the
next 12 months, 92.3% of parents cited one reason, 6.6%
cited two, and 1.1% cited three or more reasons with the
maximum being seven reasons. The proportion of par-
ents who reported one or more reasons which fall in
one of more of the five domains are as follows: 43.8%
vaccine misinformation, 18.0% safety and effective con-
cerns, 17.0% lack of knowledge about the vaccine, 16.0%
systemic barriers, 5.5% socio-cultural reasons.
Socio-demographic factors associated with parental
reasons for “no-intent” for their daughters to receive the
HPV vaccine series within the next 12 months is pre-
sented in Table 5. Lack of knowledge about the vaccine
as a reason for “no-intent” were significantly greater
among female adolescents 15 years of age (AOR: 1.37
[95% CI: 1.05–1.80]), and 16 years of age (AOR: 1.52
[95% CI: 1.13–2.05]) compared to 13 years of age; Black
non-Hispanics (AOR: 1.42 [95% CI: 1.09–1.86]), His-
panics (AOR: 1.58 [95% CI: 1.14–2.17]), and Other race/
ethnicity (AOR: 1.45 [95% CI: 1.04–2.00]) compared to
White non-Hispanic parents; mothers ≥45 years of age
Table 2 Sample characteristics of unvaccinateda female
adolescents aged 13-17 years against human papillomavirus
(HPV), National Immunization Survey - Teen, 2008 – 2012
(n = 21,467)





13 5,105 22.9 (21. 9–23.9)
14 4,722 21.1 (20.1–22.1)
15 4,256 20.7 (19.7–21.8)
16 3,936 19.2 18.2–20.3)
17 3,448 16.1 (15.2–16.9)
Race/ethnicity
White, non-Hispanic 15, 036 60.1 (58.9–61.4)
Black, non-Hispanic 2,385 15.5 (14.5–16.4)
Hispanic 2,393 16.8 (15.7–17.9)
Otherb 1,663 7.6 (6.9–8.3)





≤35,000 4,973 30.8 (29.5–32.0)
35,001–75,000 7,055 32.5 (31.3–33.7)
>75,000 9,439 36.7 (35.6–37.9)
Mother’s education
Less than high school 1,859 12.9 (11.9–14.0)
High school 4,321 26.9 (25.5–27.9)
Some college 6,393 26.8 (25.6–27.8)
College graduate 8,894 33.6 (32.5–34.7)
Mother’s marital status
Married 16,518 71.6 (70.4–72.8)
Otherc 4,949 28.4 (27.2–29.6)
Mother’s age, years
≤34 1,518 8.9 (8.1–9.7)
35–44 9,263 46.6 45.4–47.9)
≥ 45 10,686 44.4 (43.2–45.7)
Health insurance statusd
Private 14,916 63.5 (62.20–64.8)
SCHIP or Medicaid 3,732 22.5 (21.4–23.7)
IHS or Military 347 1.2 (1.0–1.3)
Other 1,123 4.8 (4.2–5.4)




No 12, 952 63.1 (61.9–64.3)
Yes 8,515 36.9 (35.7–38.1)
Table 2 Sample characteristics of unvaccinateda female
adolescents aged 13-17 years against human papillomavirus
(HPV), National Immunization Survey - Teen, 2008 – 2012
(n = 21,467) (Continued)
Survey year
2008 4,605 24.0 (22.9–25.2)
2009 4,424 21.0 (20.0–22.0)
2010 4,173 20.0 (19.0–21.0)
2011 4,761 18.4 (17.5–19.3)
2012 3,504 16.6 (15.7–17.5)
aHas had zero doses of HPV vaccine
bIncludes non-Hispanic other racial/ethnic groups and biracial
cNever married/widowed/divorced/separated
dSCHIP = State Children’s Health Insurance Program; IHS = Indian Health Service
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Table 3 Factors associated with no-intent to receivea the human papillomavirus vaccine (HPV) series among unvaccinated female
adolescents aged 13–17 years, 2008–2012 national immunization survey—teen (n = 21,467)
Characteristics Unadjusted weighted proportion (95% CI) or median Adjusted odds ratio (95%
confidence interval)No-intent to initiate (n = 12,716) Intent-to-initiate (n = 8,751)
Adolescent age, years
13 23.0 (21.7–24.4) 22.8 (21.2–24.3) 1.00
14 20.9 (19.6–22.2) 21.3 (19.8–22.9) 0.96 (0.83–1.12)
15 19.9 (18.6–21.2) 22.0 (20.2–23.7) 0.88 (0.75–1.03)
16 20.0 (18.6–21.5) 18.0 (16.5–19.6) 1.06 (0.90–1.25)
17 16.1 (15.1–17.2) 15.9 (14.5–17.3) 0.93 (0.79–1.10)
Race/ethnicity of teen
White, non-Hispanic 62.0 (60.3–63.6) 57.4 (55.4–59.4) 1.00
Black, non-Hispanic 15.3 (14.1–16.4) 15.8 (14.2–17.3) 0.96 (0.81–1.12)
Hispanic 15.2 (13.8–16.6) 19.3 (17.5–21.1) 0.79 (0.66–0.95)
Otherb 7.6 (6.8–8.5) 7.6 (6.3–8.9) 0.96 (0.76–1.22)
Number of people in the household
per person over two
3.79 (3.74–3.84) 3.75 (3.69–3.81) 1.05 (1.01–1.10)
Annual household, US dollars
≤35,000 28.4 (26.7–29.8) 34.2 (32.5–36.5) 1.00
35,001–75,000 34.2 (32.7–35.7) 30.0 (28.2–31.8) 1.21 (1.02–1.44)
>75,000 37.5 (36.0–39.1) 35.5 (33.8–37.3) 1.08 (0.90–1.30)
Mother’s education
Less than high school 11.4 (10.1–12.7) 15.3 (13.6–16.9) 1.00
High school 25.9 (24.4–27.4) 27.9 (26.0–29.8) 1.11 (0.89–1.39)
Some college 28.3 (26.9–29.7) 24.5 (22.9–26.1) 1.44 (1.16–1.79)
College graduate 34.4 (33.0–35.9) 32.4 (30.7–34.0) 1.28 (1.03–1.60)
Mother’s marital status
Otherc 26.5 (24.9–28.1) 31.3 (29.4–33.2) 1.00
Married 73.5 (71.9–75.1) 68.7 (66.9–70.6) 1.13 (0.98–1.31)
Mother’s age, years
≤34 7.9 (7.0–8.8) 10.5 (9.1–11.8) 1.00
35–44 46.4 (44.8–48.1) 47.0 (45.0–48.9) 1.22 (0.99–1.51)
≥45 45.7 (44.1–47.3) 42.6 (40.7–44.5) 1.32 (1.06–1.65)
Health insurance statusd
Private 64.8 (63.2–66.4) 61.5 (59.5–63.5) 1.00
SCHIP or Medicaid 20.7 (19.3–22.1) 25.3 (23.3–27.2) 0.92 (0.77–1.11)
IHS or Military 1. (0.8–1.2) 1.4 (1.0–1.7) 0.73 (0.52–1.03)
Other 5.4 (4.5–6.4) 3.9 (3.1–4.7) 1.36 (1.05–1.75)
Uninsured 8.1 (7.1–9.1) 8.0 (6.8–9.2) 1.06 (0.84–1.35)
Health care provider recommended
the HPV vaccine
Yes 31.2 (29.8–32.7) 45.4 (43.5–47.3) 1.00
No 68.8 (67.3–70.3) 54.6 (52.7–56.5) 2.02 (1.82–2.53)
Survey year
2008 22.4 (21.0–23.9) 26.4 (24.5–28.3) 1.00
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(AOR: 1.48 [95% CI: 1.00–2.22]) and 35–44 years of age
(AOR: 1.56 [95% CI: 1.06–2.31]) compared to mothers
(≤34 years of age. Compared to mothers with less than
high school education, mothers with high school educa-
tion (AOR: 1.52 [95% CI: 1.02–2.28]), some college educa-
tion (AOR: 1.79 [95% CI: 1.20–2.68]), or with a graduate
education (AOR: 1.84 [95% CI: 1.21–2.81]) had greater
odds to report “Safety and Effectiveness Concerns”.
Parents who did not receive a health care provider
recommendation for their daughter to receive the
HPV vaccine series had greater odds to report “Sys-
temic Barriers” (AOR: 6.84 [95% CI: 5.25–8.91]) and/
or “Vaccine Misinformation” (AOR: 1.18 [95% CI:
1.02–1.35]) compared to those parents of female ado-
lescents with a provider recommendation. An increas-
ing number of people in the household was also
associated with greater odds to report vaccine misin-
formation (AOR: 1.08 [95% CI: 1.03–1.14]).
The odds of reporting “Socio-cultural Barriers” were
significantly greater among female adolescents 15 years
of age (AOR: 1.57 [95% CI: 1.09–2.26]) and, 17 years of
age (AOR: 1.52 [95% CI: 1.01–2.30]) compared to 13
years of age; among Black non-Hispanic parents (AOR:
1.63 [95% CI: 1.15–2.32]) compared to White non-
Hispanic parents; among parents who reported their an-
nual household income as > $75,000 (AOR: 1.91 [95%
CI: 1.14–3.19]), and $35,001–$75,000 (AOR: 1.62 [95%
CI: 1.04–2.55]) compared to parents who reported their
annual household income as ≤ $35,000. Parents in survey
years 2009–2012 were more likely to report safety and
effectiveness concerns compared to parents in the survey
year 2008. Additionally, parents in the survey year 2012
(AOR: 1.57 [95% CI: 1.17–2.09]) had higher odds of
reporting systemic barriers compared to parents in the
survey year 2008.
Discussion
This study is one of the first to identify sub-groups of
parents across different socio-demographic factors who
reported “no-intent” and reasons for “no-intent” for their
daughters to receive the HPV vaccine series within the
next 12 months in a nationally representative sample of
unvaccinated female adolescents 13–17 years of age.
Though the proportion of HPV vaccine uptake among
female adolescents has significantly increased over time,
this study found that three out of five parents of unvac-
cinated females reported “no-intent” to vaccinate their
daughters within the next 12 months (2008: 55.1% ;
2009: 60.6% ; 2010: 64.6% ; 2011: 59.8% ; 2012: 60.3%).
In addition, this study describes the patterns over time
in socio-demographic factors of parents who reported
“no-intent”. The study findings provide useful informa-
tion to develop strategies for outreach and education
geared toward health care providers whose lack of rec-
ommendation for the HPV vaccine significantly influ-
enced parental “intent” for their daughters to receive the
HPV vaccine series, to address parents’ concerns about
the HPV vaccine across different socio-demographic
characteristics. This may help improve the vaccine up-
take among females 13–17 years of age.
Consistent with previous reports [25, 32, 39–41], pro-
vider recommendation was observed to significantly in-
fluence parental “intent” for their daughters to receive
the HPV vaccine series; more than sixty percent of par-
ents of unvaccinated females received no recommenda-
tion from their health care provider (2008: 70.1% ; 2009:
62.8% ; 2010: 63.4% ; 2011: 60.3% ; 2012: 55.9%). Among
parents with “no-intent” who reported systemic barriers,
21.6% received a provider recommendation, compared
to 3.9% of parents who did not receive a provider
recommendation for their adolescent daughters.
Among parents with “no-intent” who reported Safety
and Effectiveness Concerns, 28.1% received a provider
recommendation compared to 13.3% of parents who
did not receive a provider recommendation for their
adolescent daughters. Lastly, compared to parents in
the survey year 2008, parents in the survey years
2009–2012 were significantly more likely to report
“no-intent” and cite Safety and Effectiveness Concerns
as their reason, yet less like to cite Lack of Know-
ledge about the Vaccine as a reason for “no-intent”.
This may suggest that over time knowledge about the
vaccine has increased, but along with that the safety
and effectiveness concerns have also increased. These
findings not only highlight the importance of a
provider recommendation, but also the missed
Table 3 Factors associated with no-intent to receivea the human papillomavirus vaccine (HPV) series among unvaccinated female
adolescents aged 13–17 years, 2008–2012 national immunization survey—teen (n = 21,467) (Continued)
2009 21.4 (19.8–22.8) 20.5 (19.0–22.0) 1.30 (1.10–1.52)
2010 21.7 (20.4–23.1) 17.4 (16.0–18.9) 1.57 (1.33–1.86)
2011 18.2 (17.1–19.3) 18.8 (17.3–20.2) 1.25 (1.06–1.47)
2012 16.3 (15.4–17.4) 17.0 (15.5–18.4) 1.26 (1.06–1.50)
aNo-intent to initiate the HPV vaccine series in the next 12 months
bIncludes non-Hispanic other racial/ethnic groups and biracial
cNever married/widowed/divorced/separated/deceased
dSCHIP = State Children’s Health Insurance Program; IHS = Indian Health Service
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Table 4 Patterns in no-intenta for the HPV vaccine according to socio-demographic factors, National Immunization Survey - Teen,













13 12.3 (10.4–14.1) 13.7 (11.8–15.5) 15.2 (13.3–17.1) 14.2 (12.5–15.9) 14.0 (12.0–15.9)
14 11.4 (9.4–13.3) 13.8 (11.8–15.8) 12.4 (10.5–14.3) 12.8 (11.1–14.4) 12.3 (10.5–14.1)
15 11.0 (9.2–12.9) 12.3 (10.7–14.0) 13.5 (11.6–15.5) 11.4 (10.0–12.9) 11.3 (9.5–13.1)
16 11.9 (10.0–13.8) 11.9 (9.4–14.3) 12.1 (10.3–13.9) 12.4 (10.5–14.2) 11.7 (9.7–13.8)
17 9.3 (7.8–10.8) 9.2 (7.9–10.5) 11.8 (10.1–13.5) 8.4 (7.2–9.5)c 9.6 (7.8–11.3)
Race/ethnicity
White, non–Hispanic 33.9 (31.3–36.5) 38.4 (35.8–41.0) 39.7 (37.1–42.2) 38.2 (35.8–40.5) 35.8 (33.2–38.4)
Black, non-Hispanic 9.0 (7.5–10.5) 8.9 (7.5–10.3) 10.9 (9.2–12.6) 8.3 (6.8–9.8) 8.5 (6.6–10.3)
Hispanic 9.5 (7.4–11.6) 9.5 (7.2–11.8) 10.2 (8.0–12.3) 7.7 (6.3–9.1) 8.2 (6.5–10.0)
Otherb 3.5 (2.5–4.4) 4.1 (3.1–5.1) 4.4 (3.4–5.4) 5.0 (3.7–6.2) 6.5 (4.8–8.1)
Annual household income, US $
≤35,000 15.8 (13.5–18.2) 15.6 (13.5–17.7) 19.2 (16.8–21.7) 17.8 (15.8–19.9) 16.4 (13.9–18.8)
35,001–75,000 20.3 (18.1–22.5) 20.8 (18.3–23.2) 20.7 (18.7–22.8) 21.0 (18.9–23.2) 19.4 (17.1–21.6)
>75,000 19.7 (17.6–21.9) 24.6 (22.2–26.9)e 25.1 (22.8–27.3)e 20.2 (18.5–21.9)f,g 23.2 (20.9–25.4)
Mother’s education
Less than high school 8.1 (6.0–10.1) 6.9 (5.3–8.5) 7.6 (5.6–9.7) 5.2 (4.0–6.4) 5.6 (3.8–7.4)
High school 15.3(13.3–17.4) 16.6 (13.9–19.3) 16.9 (14.9–18.9) 15.6(13.6–17.6) 12.5 (10.6–14.4)
Some college 15.7 (13.8–17.6) 15.9 (14.2–17.5) 18.9 (16.9–20.9) 16.5(14.7–18.2) 18.3 (16.0–20.6)
College graduate 16.8 (14.8–18.8) 21.6 (19.5–23.6)e 21.5 (19.4–23.6)e 21.9(19.9–23.8)e 22.5 (20.3–24.7)e
Mother’s marital status
Married 42.2 (39.4–45.1) 46.7 (44.0–49.4) 48.9 (46.1–51.6) 40.9 (38.5–43.3) 40.7 (37.9–43.5)
Otherc 13.7 (11.5–15.8) 14.2(11.7–16.7) 16.2 (14.0–18.3) 18.2 (16.0–20.4)e 18.2 (15.6–20.8)
Mother’s age, years
≤34 4.5 (3.2–5.7) 3.7 (2.9–4.6) 5.5 (4.1–7.0) 5.5 (4.1–6.8) 4.4 (3.1–5.7)
35–44 28.1 (25.4–30.8) 29.1 (26.4–31.8) 28.7 (26.1–31.3) 26.6 (24.4–28.8) 25.9 (23.3–28.5)
≥45 23.3 (21.1–25.1) 28.0 (25.6–30.5)e 30.8 (28.4–33.2)e 27.0 (24.8–29.2) 28.6 (26.0–31.1)e
Health insurance statusd
Private 37.0 (34.3–39.7) 40.0 (37.4–42.7) 41.4 (38.8–44.0) 37.9 (35.5–40.4) 37.6 (34.8–40.3)
SCHIP or Medicaid 11.5 (9.4–13.5) 10.2 (8.7–11.7) 13.7 (11.6–15.9) 13.2 (11.5–14.9) 13.8 (11.4–16.1)
IHS or Military 0.4 (0.2–0.6) 0.7 (0.4–1.0) 0.8 (0.5–1.1) 0.6 (0.3–0.8) 0.6 (0.2–1.0)
Other 2.4 (1.7–3.0) 5.0 (2.9–7.1) 2.5 (1.9–3.1) 3.3 (2.3–4.2) 3.3 (2.3–4.3)
Uninsured 4.6 (3.2–6.1) 5.0 (3.6–6.3) 6.6 (4.8–8.4) 4.1 (3.2–5.1) 3.7 (2.7–4.7)
Healthcare provider recommended HPV vaccine
Yes 11.6 (9.9–13.2) 18.9 (16.7–21.1) 20.1 (17.8–22.5) 21.5 (19.4–23.6) 24.0 (21.5–26.4)
No 44.3 (41.5–47.2) 42.0 (39.2–44.8) 44.9(42.2–47.6) 37.6 (35.2–40.0) 35.0 (32.2–37.7)e,f,g
aNo-intent to initiate the HPV vaccine series in the next 12 months
bIncludes non-Hispanic other racial/ethnic groups and biracial
cNever married/widowed/divorced/separated
dSCHIP = State Children’s Health Insurance Program; IHS = Indian Health Service
eSignificantly different compared to the survey year 2008
fSignificantly different compared to the survey year 2009
gSignificantly different compared to the survey year 2010
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Table 5 Multivariable logistic regression analyses of factors associated with reasons for no-intent to receivea human papillomavirus
vaccine (HPV) series among unvaccinated female adolescents aged 13–17 years, National Immunization Survey - Teen, 2008–2012
(n = 12,274b)
Adjusted odds ratio (95% confidence interval)c











13 1.00 1.00 1.00 1.00 1.00
14 0.99 (0.78–1.27) 1.15 (0.86–1.52) 0.90 (0.74–1.10) 1.27 (0.95–1.70) 0.78 (0.54–1.13)
15 0.94 (0.75–1.19) 0.93 (0.69–1.24) 0.88 (0.72–1.08) 1.37 (1.05–1.80) 1.57 (1.09–2.26)
16 1.01 (0.79–1.30) 0.84 (0.63–1.13) 0.76 (0.61–0.93) 1.52 (1.13–2.05) 1.29 (0.82–2.01)
17 1.00 (0.78–1.29) 1.01 (0.76–1.36) 0.69 (0.56–0.84) 1.10 (0.83–1.47) 1.52 (1.01–2.30)
Race/ethnicity
White, non–Hispanic 1.00 1.00 1.00 1.00 1.00
Black, non–Hispanic 0.75 (0.57–0.98) 1.05 (0.78–1.41) 0.98 (0.80–1.20) 1.42 (1.09–1.86) 1.63 (1.15–2.32)
Hispanic 0.80 (0.59–1.10) 1.02 (0.75–1.38) 0.93 (0.73–1.19) 1.58 (1.14–2.17) 1.14 (0.72–1.81)
Otheri 0.70 (0.52–0.94) 1.39 (1.00–1.94) 0.80 (0.62–1.02) 1.45 (1.04–2.00) 0.88 (0.54–1.44)
Number of people in the household,
per person over two
0.86 (0.81–0.91) 0.97 (0.91–1.04) 1.08 (1.03–1.14) 1.00 (0.92–1.09) 1.09 (0.98–1.22)
Annual household income, US $
≤35,000 1.00 1.00 1.00 1.00 1.00
35,001–75,000 1.13 (0.88–1.47) 0.64 (0.49–0.83) 1.03 (0.84–1.27) 1.20 (0.91–1.59) 1.62 (1.04–2.55)
>75,000 1.10 (0.84–1.46) 0.62 (0.46–0.83) 1.04 (0.83–1.31) 0.95 (0.70–1.30) 1.91 (1.14–3.19)
Mother’s education
Less than high school 1.00 1.00 1.00 1.00 1.00
High school 1.52 (1.02–2.28) 0.77 (0.52–1.13) 1.12 (0.82–1.53) 0.95 (0.66–1.38) 1.18 (0.58–2.43)
Some college 1.79 (1.20–2.68) 0.76 (0.53–1.10) 1.24 (0.91–1.68) 0.76 (0.53–1.08) 1.32 (0.67–2.59)
College graduate 1.84 (1.21–2.81) 0.82 (0.56–1.20) 1.51 (1.10–2.06) 0.48 (0.34–0.69) 1.55 (0.74–3.24)
Mother’s marital status
Otherj 1.00 1.00 1.00 1.00 1.00
Married 1.22 (0.98–1.52) 1.18 (0.92–1.52) 1.09 (0.88–1.34) 0.88 (0.63–1.22) 0.71 (0.51–0.98)
Mother’s age, years
≤34 1.00 1.00 1.00 1.00 1.00
35–44 0.99 (0.71–1.36) 0.91 (0.63–1.33) 0.85 (0.64–1.13) 1.56 (1.06–2.31) 0.55 (0.31–0.98)
≥45 0.86 (0.62–1.21) 0.98 (0.67–1.43) 0.92 (0.69–1.23) 1.48 (1.00–2.22) 0.56 (0.31–1.01)
Health insurance statusk
Private 1.00 1.00 1.00 1.00 1.00
SCHIP or Medicaid 1.21 (0.93–1.56) 0.97 (0.73–1.30) 0.83 (0.66–1.02) 0.73 (0.54–1.00) 1.34 (0.86–2.07)
IHS or Military 1.20 (0.71–2.06) 0.76 (0.35–1.70) 0.75 (0.47–1.19) 0.83 (0.42–1.64) 1.63 (0.76–3.49)
Other 0.88 (0.63–1.22) 0.99 (0.66–1.47) 0.87 (0.64–1.19) 1.32 (0.77–2.27) 1.31 (0.74–2.34)
Uninsured 0.98 (0.69–1.38) 1.06 (0.73–1.52) 0.86 (0.65–1.15) 1.30 (0.91–1.88) 0.69 (0.38–1.25)
Healthcare provider recommended HPV vaccine
Yes 1.00 1.00 1.00 1.00 1.00
No 0.42 (0.36–0.49) 6.84 (5.25–8.91) 1.18 (1.02–1.35) 0.86 (0.69–1.07) 0.49 (0.38–0.63)
Survey Year
2008 1.00 1.00 1.00 1.00 1.00
2009 1.45 (1.09–1.93) 0.93 (0.70–1.24) 0.80 (0.64–0.99) 0.96 (0.71–1.30) 2.07 (1.39–3.07)
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opportunities health care providers have to effectively
communicate the health benefits of the HPV vaccine,
specifically with regard to vaccine safety and effective-
ness. Additionally, a provider recommendation would
help to facilitate an improvement in vaccine accept-
ance and vaccination intentions [42–45].
In this study, mothers with a high school education or
higher were more likely to report “no-intent” for their
daughters to receive the HPV vaccine series within the
next 12 months. Other studies have reported similar
findings [28, 35, 46]. In addition, we found mothers with
higher education were more likely to cite Safety and Ef-
fectiveness Concerns as a reason for “no-intent”. This
highlights the importance of appropriately addressing
safety and effectiveness concerns among all mothers,
particularly those with higher education. Also, we found
older mothers were more likely to report “no-intent”
compared to younger mothers, and this result is also
consistent with other studies [47, 48]. Older mothers,
Black non-Hispanic, Hispanic, and parents of “Other”
ethnicity were more likely to report “Lack of Knowledge
about the Vaccine” as a reason for “no-intent”. Consist-
ent with our finding, recent studies in Latino parents’ re-
ported low HPV vaccine knowledge as one of the main
barriers to vaccine receipt [41, 49]. Furthermore, parents
of older adolescents Black non-Hispanic and parents
with annual household income more than $35,000, and
were more likely to cite “Socio-cultural Barriers”. These
findings highlight the importance of disseminating
health communication about HPV across various
demographics.
Overall, this study found that the patterns in socio-
demographic factors between proportions of parents
reporting “no-intent” were similar across years 2008–
2012. These patterns highlight that HPV vaccine accept-
ance beliefs among parents have not significantly chan-
ged over time, thereby impacting vaccine uptake among
certain sub-groups of adolescents identified in this
study. Considering that the HPV vaccine is intended
to protect against HPV infection and pre-cancerous
lesions caused by high-risk HPV types, delaying the initi-
ation or refusing the vaccine altogether by these sub-
groups of parents for their daughters is a matter of public
health concern.
We acknowledge that the analysis of this study has
some limitations. In the years 2008–2010, during which
cell-phone-only households were increasing, the NIS-
Teen sampling frame included only households that had
landline telephones. For the first time in 2011, NIS-Teen
utilized a dual-frame (both landline and cell-phone sam-
pling frames) but the cellular household response rate
was low compared to the landline household response
rate in both 2011 and 2012. As a result, non-response
and non-coverage bias may exist, even after adjusting
sampling weights. Geographic region in the US, which
we did not consider in our study, may be helpful to bet-
ter understand and address parents’ reported reasons for
“no-intent” to vaccinate their adolescent daughters [24].
Also, information about adolescent daughter being a first
child or not would shed some insights into parents’
awareness of HPV vaccine. Lastly, parental no-intent to
vaccinate their 13–17 years old daughters within the
next 12 months might not necessarily result in not vac-
cinating beyond the 12-month period, as intention and
action often vary.
Conclusions
This study identified sub-groups of parents across differ-
ent socio-demographic factors with “no-intent” for their
daughters of 13–17 years of age to receive the HPV vac-
cine series within the next 12 months, and their reasons
for such a decision. Developing strategies that target
educational tools towards the identified sub-groups of
parents about the purpose, safety, and efficacy of the
HPV vaccine, and HPV infection, may help increase
HPV vaccination acceptance, and initiation and comple-
tion rates among female adolescents. In addition, strat-
egies to improve vaccine uptake should focus on
developing communication tools for health care pro-
viders to better address parents’ reasons for “no-intent”
Table 5 Multivariable logistic regression analyses of factors associated with reasons for no-intent to receivea human papillomavirus
vaccine (HPV) series among unvaccinated female adolescents aged 13–17 years, National Immunization Survey - Teen, 2008–2012
(n = 12,274b) (Continued)
2010 2.83 (2.16–3.70) 0.93 (0.70–1.24) 0.85 (0.69–1.04) 0.63 (0.47–0.85) 0.95 (0.60–1.52)
2011 2.18 (1.68–2.83) 0.87 (0.65–1.16) 1.02 (0.83–1.25) 0.66 (0.50–0.87) 1.14 (0.75–1.72)
2012 1.45 (1.09–1.93) 1.57 (1.17–2.09) 0.67 (0.53–0.84) 0.64 (0.47–0.87) 1.47 (0.95–2.27)
a“no-intent” to initiate the HPV vaccine series in the next 12 months; bSample size with complete data on all the covariates in the logistic regression models
cLogistic regression models include all the variables listed; dSafety and effectiveness concerns category included the cited reasons of safety and side effects, new
vaccine, need more information, and effectiveness concerns; eSystemic barriers includes: health care provider not recommended, cost, vaccine not available, no
doctor/obstetrician/gynecologist/doctor visit scheduled, and not a school requirement; fVaccine misinformation includes: not needed/not necessary, adolescent
not sexually active, not appropriate age, and concern of increased sexual activity; glack of knowledge about the vaccine included the response lack of knowledge;
and hSociocultural reasons included: family/parental decision, do not believe in immunizations, and against religion/orthodox
iIncludes non-Hispanic other racial/ethnic groups and biracial; jNever married/widowed/divorced/separated; kSCHIP = State Children’s Health Insurance Program;
IHS = Indian Health Service
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in support of making recommendations for vaccinating
the adolescents during their health-care encounter.
Implications and contribution
This study identified subgroups of parents across differ-
ent socio-demographics and the reported reasons for
no-intent to vaccinate their daughters with the HPV vac-
cine. The socio-demographic characteristics of such par-
ents with no-intent as identified in this study have
implications for developing strategies to address the
various concerns (reasons) reported by the parents with
“no-intent” to vaccinate their adolescent daughters with
HPV vaccine. Also, communication tools focused on
health care providers would address the significant sys-
temic failure due to lack of provider recommendation.
These efforts may help increase HPV vaccine accept-
ance. Future studies should focus on the impact of strat-
egies developed on HPV vaccine uptake among the
subgroups of parents identified in this study.
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